AstraZeneca announces $ 3.5 billion of capital investment in the United States to focus on expanding the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment with the aim to create more than a thousand new and high-skilled jobs.
AstraZeneca’s expanding footprint in the US includes, among others:
- An R&D centre in Kendall Square, Cambridge, Massachusetts
- A manufacturing facility for biologics in Maryland
- Cell therapy manufacturing capacity on the West and East Coasts
- Specialty manufacturing in Texas
These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve $80 billion in total revenue by 2030 as set out in May this year. A key element of their strategy is accelerating the Company’s development in the United States. The US is AstraZeneca’s largest market, generating 44 per cent of its total revenue.
The post appeared first on .